Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study.

Shuichi MizutaMasashi SawaHisashi TsurumiKana MatsumotoKotaro MiyaoTakeshi HaraTakeshi TakahashiReona SakemuraHiroshi KojimaAkio KohnoMari S ObaSatoshi MoritaJunichi SakamotoNobuhiko Emi

Published in: International journal of clinical oncology (2018)

Current data demonstrate that patients treated with dasatinib who displayed a high Cmin/D/W value and/or advanced PS were at a high risk for altered treatment.

Keyphrases

chronic myeloid leukemia
electronic health record
big data
artificial intelligence
smoking cessation
replacement therapy